Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
111.34M | 85.89M | 70.70M | 50.61M | 30.32M | Gross Profit |
35.81M | 29.26M | 23.16M | 17.70M | 11.19M | EBIT |
24.57M | 22.62M | 16.90M | 12.38M | 6.48M | EBITDA |
27.96M | 25.78M | 20.02M | 14.46M | 8.97M | Net Income Common Stockholders |
16.38M | 17.24M | 12.87M | 10.14M | 4.79M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
7.53M | 18.13M | 20.43M | 31.80M | 17.50M | Total Assets |
175.89M | 154.40M | 128.66M | 107.17M | 87.00M | Total Debt |
4.90M | 5.36M | 5.14M | 5.25M | 5.29M | Net Debt |
-2.63M | -12.77M | -15.29M | -26.55M | -12.22M | Total Liabilities |
43.78M | 34.84M | 32.74M | 21.13M | 16.31M | Stockholders Equity |
132.11M | 119.56M | 95.92M | 86.04M | 70.69M |
Cash Flow | Free Cash Flow | |||
28.76M | 16.67M | 15.40M | 14.23M | 12.12M | Operating Cash Flow |
28.84M | 16.79M | 15.73M | 14.33M | 12.15M | Investing Cash Flow |
-21.50M | -14.82M | -18.53M | -3.24M | -1.46M | Financing Cash Flow |
-17.64M | -4.06M | -8.85M | 3.11M | 3.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | £360.26M | 21.72 | 13.02% | 1.67% | 29.64% | -7.27% | |
77 Outperform | £401.53M | 10.20 | 35.97% | 4.14% | 22.39% | 179.53% | |
77 Outperform | £286.53M | 48.50 | 5.78% | 0.89% | 20.65% | -17.11% | |
73 Outperform | £309.03M | 8.46 | 14.26% | 3.26% | -8.18% | 90.18% | |
66 Neutral | $4.51B | 12.29 | 5.40% | 3.67% | 4.15% | -12.21% | |
64 Neutral | £1.35B | 46.00 | 12.82% | 1.16% | 4.54% | -2.11% | |
56 Neutral | £145.16M | 29.69 | -3.96% | 16.04% | -16.16% | -145.46% |
Elixirr International plc has announced the grant of share options to key managerial figures, Clare Filby and Christopher Jordan, as part of its unapproved share option plan. These options, which cover a total of 119,048 ordinary shares each, represent approximately 0.49% of the company’s issued share capital and are set at an exercise price of 840p per share with a five-year vesting period. This move is indicative of Elixirr’s strategy to incentivize its leadership team, potentially enhancing its market position and aligning managerial interests with shareholder value.
The most recent analyst rating on (GB:ELIX) stock is a Buy with a £850.00 price target. To see the full list of analyst forecasts on Elixirr International Plc stock, see the GB:ELIX Stock Forecast page.
Elixirr International plc has announced its plans to transition from the AIM to the Main Market of the London Stock Exchange, a move reflecting its growth and ambition. The transition is expected to complete by July 1, 2025, and aims to enhance Elixirr’s market positioning, with the existing AIM listing being canceled. This strategic shift is part of Elixirr’s broader growth strategy, which will be further discussed during their Capital Markets Day event, showcasing their innovative solutions and partnerships.
The most recent analyst rating on (GB:ELIX) stock is a Buy with a £850.00 price target. To see the full list of analyst forecasts on Elixirr International Plc stock, see the GB:ELIX Stock Forecast page.
Elixirr International plc announced recent transactions involving its ordinary shares, including the transfer of shares to former shareholders of acquired businesses and a sale by its Non-Executive Chairman. These transactions reflect ongoing adjustments in the company’s shareholding structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:ELIX) stock is a Buy with a £850.00 price target. To see the full list of analyst forecasts on Elixirr International Plc stock, see the GB:ELIX Stock Forecast page.
Elixirr International plc has announced the posting of its 2024 Annual Report and AGM notice, along with the final dividend timetable for the year ended 31 December 2024. The AGM is scheduled for 24 June 2025, and the final dividend of 11.5p per share will be paid on 20 August 2025. This announcement underscores Elixirr’s commitment to transparency and shareholder engagement, potentially strengthening its market position and stakeholder relations.
The most recent analyst rating on (GB:ELIX) stock is a Buy with a £850.00 price target. To see the full list of analyst forecasts on Elixirr International Plc stock, see the GB:ELIX Stock Forecast page.
Elixirr International plc is set to host a Capital Markets Day on June 4, 2025, at its London office, inviting institutional investors and analysts to gain insights into its growth strategy and future plans. The event will feature interactive sessions led by global partners, showcasing Elixirr’s innovative digital, data, tech, and AI solutions, including collaborations with Meta and British Cycling, highlighting the company’s commitment to transforming customer experiences and advancing its industry positioning.
The most recent analyst rating on (GB:ELIX) stock is a Buy with a £850.00 price target. To see the full list of analyst forecasts on Elixirr International Plc stock, see the GB:ELIX Stock Forecast page.
Elixirr International plc is set to host a Capital Markets Day on June 4, 2025, at its London office, inviting institutional investors and analysts to gain insights into its growth strategy and future plans. The event will feature interactive sessions with global partners, showcasing Elixirr’s advanced digital, data, tech, and AI solutions, including collaborations with major clients like Meta and British Cycling, highlighting the company’s innovative approach and industry impact.
The most recent analyst rating on (GB:ELIX) stock is a Buy with a £850.00 price target. To see the full list of analyst forecasts on Elixirr International Plc stock, see the GB:ELIX Stock Forecast page.
Elixirr International plc has announced that its Employee Benefit Trust has purchased 308,786 ordinary shares at 780p per share, now holding 3.29% of the company’s issued share capital. This strategic move, guided by Apex Group Fiduciary Services Limited, aims to ensure sufficient shares for employee incentives and new partners, supporting the company’s growth strategy without diluting equity, thereby strengthening its market position.
Elixirr International Plc reported a record financial performance for the fiscal year 2024, driven by strong client demand and geographic expansion, with a 30% increase in revenue to £111.3 million. The company plans to move to the Main Market of the London Stock Exchange, which is expected to enhance access to institutional capital and support long-term growth. This strategic move follows significant growth since 2019, including revenue and EBITDA quadrupling and several acquisitions. The company remains confident in its outlook for 2025, supported by high demand for its technology-led advisory services and recent strategic acquisitions, such as the Hypothesis Group, which bolstered its capabilities in the US market.